TY - JOUR
T1 - Chronic myelogenous leukemia, version 1.2014
T2 - Featured updates to the NCCN guidelines
AU - O'Brien, Susan
AU - Radich, Jerald P.
AU - Abboud, Camille N.
AU - Akhtari, Mojtaba
AU - Altman, Jessica K.
AU - Berman, Ellin
AU - DeAngelo, Daniel J.
AU - Deininger, Michael
AU - Devine, Steven
AU - Fathi, Amir T.
AU - Gotlib, Jason
AU - Jagasia, Madan
AU - Kropf, Patricia
AU - Moore, Joseph O.
AU - Pallera, Arnel
AU - Pinilla-Ibarz, Javier
AU - Reddy, Vishnu V.B.
AU - Shah, Neil P.
AU - Douglas Smith, B.
AU - Snyder, David S.
AU - Wetzler, Meir
AU - Gregory, Kristina
AU - Sundar, Hema
PY - 2013/11/1
Y1 - 2013/11/1
N2 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).
AB - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).
UR - http://www.scopus.com/inward/record.url?scp=84891954191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891954191&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2013.0157
DO - 10.6004/jnccn.2013.0157
M3 - Review article
C2 - 24225967
SN - 1540-1405
VL - 11
SP - 1327
EP - 1340
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 11
ER -